Genextra

Decisions run through co-founders Gabriele Bavagnoli and Francesco Riviera, who have led the firm since 1999. The team operates leanly from Milan, with final investment authority resting with the managing partners. No external investment committee is disclosed.

Genextra sources primarily through Italian and Swiss university spinout networks, research-hospital collaborations, and founder referrals built over two decades. The firm rarely participates in auction processes, leaning on proprietary relationships with European academic institutions and early-stage biotech syndicates.

Genextra functions as a multi-family office deploying permanent capital from a small circle of European industrial families. It does not raise blind-pool funds with fixed investment periods or LP redemption rights, which allows hold periods that routinely exceed 15 years.

Genextra focuses on seed through Series B rounds, with a preference for first institutional checks into university spinouts and founder-led life sciences companies. The firm also participates in later syndicated rounds through co-investment vehicles.

Genextra is concentrated in biotechnology, medical devices, diagnostics, and digital health. There is no public record of the firm making investments outside of healthcare and life sciences, and its nearly 25-year track record is entirely sector-specific.

Capital derives from two Italian entrepreneurial families and a small number of additional European industrial families brought into the platform over time. The specific family names have not been publicly disclosed, and the firm does not disclose total assets under management.

Genextra holds positions for a decade or more, exiting through trade sales to strategic acquirers or, when warranted, public-market liquidity events. The January 2023 Molmed tender offer to AGC Biologics exemplifies the firm's willingness to exit after 20-plus years of sponsorship when a strategic buyer offers full value.